Short-term high-dose atorvastatin for periprocedural myocardial infarction prevention in patients with renal...

Area of Science:

• Cardiology
• Nephrology
• Pharmacology

Background:

• Short-term high-dose atorvastatin before percutaneous coronary intervention (PCI) is known to reduce periprocedural myocardial infarction (pMI) in high-risk patients.
• The efficacy of this strategy in patients with chronic kidney disease (CKD) remains unclear.
• Previous observations indicated no reduction in contrast-induced nephropathy (CIN) with atorvastatin in CKD patients undergoing elective procedures.

Purpose of the Study:

• To evaluate the effect of short-term high-dose atorvastatin on pMI in patients with CKD undergoing elective PCI.
• To analyze pMI rates in a subgroup of CKD patients from a larger trial investigating CIN.

Main Methods:

• A post-hoc analysis of 161 patients with estimated creatinine clearance < 60 ml/min who underwent PCI.
• Patients received either 80 mg/day atorvastatin or placebo for 48 hours before the procedure.
• Creatine kinase myocardial isoenzyme (CK-MB) levels were measured post-PCI to define pMI (CK-MB > 3x upper reference limit).

Main Results:

• The incidence of pMI was significantly lower in the atorvastatin group (10.4%) compared to the placebo group (23%) (P < 0.05).
• Multivariate analysis identified high-dose atorvastatin pretreatment as an independent predictor of reduced pMI risk (OR 0.39, 95% CI 0.16-0.96, P < 0.05).
• No significant benefit was observed regarding CIN prevention.

Conclusions:

• Short-term high-dose atorvastatin administration effectively reduces pMI in patients with renal dysfunction undergoing elective PCI.
• The study confirms no protective effect of this statin regimen against CIN in this patient population.
• High-dose atorvastatin is a potential strategy to mitigate pMI risk in CKD patients undergoing PCI.